Business Context and Reporting Period
This Form 8-K was filed by Conversion Labs, Inc. (not Lifemd, Inc.) on February 28, 2020, reporting events that occurred on February 25, 2020. The filing details the entry into material definitive agreements involving the repayment of convertible promissory notes and the amendment of associated warrants with two lenders: Alpha Capital Anstalt and Brio Capital Master Fund, Ltd.
Key Financial Metrics and Agreements
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. The primary financial data relates to debt repayment and warrant restructuring:
- Total Debt Repaid: $906,645.23 in principal and interest.
- Alpha Capital Anstalt Repayment: $520,000 (2019 Note) and $224,145.23 (2018 Note).
- Brio Capital Master Fund Repayment: $162,500 (2019 Note).
- Warrant Exercise Price Reduction: All amended warrants had their exercise price reduced from $0.28 to $0.135 per share.
- Warrant Share Increase: The total number of shares issuable under the amended warrants increased significantly due to the lower exercise price.
Material Changes Versus Prior Period
The filing does not contain comparative financial data against a prior period. The material changes reported are specific to the restructuring of debt instruments:
- Alpha 2019 Warrant: Shares issuable increased from 1,826,087 to 3,787,439.
- Alpha 2018 Warrant: Shares issuable increased from 1,956,522 to 4,057,972.
- Brio 2019 Warrant: Shares issuable increased from 570,652 to 1,183,575.
- Brio 2018 Warrant: Shares issuable increased from 434,783 to 466,989.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of future risks. The primary contingency noted is the potential dilution to existing shareholders resulting from the increased number of shares issuable under the amended warrants. The full text of the amendment agreements is referenced as an exhibit to be filed in the next quarterly report on Form 10-Q.
Investor Verification Checklist
- Verify the total cash outflow of approximately $906,645 used to repay the notes and its impact on current liquidity.
- Calculate the total potential dilution from the newly amended warrants (approx. 9.5 million shares at $0.135/share).
- Confirm the company's current cash balance post-repayment to assess runway.
- Review the upcoming Form 10-Q for the full text of the amendment agreements and any additional terms.
- Note the discrepancy between the requested company name (Lifemd, Inc.) and the actual registrant (Conversion Labs, Inc.).